Inhibikase Therapeutics (IKT) Cash from Financing Activities (2020 - 2026)
Inhibikase Therapeutics' Cash from Financing Activities was -$14,489 in Q2 2026, compared with $31,771 a year earlier.
Powered by 
Analysis
Inhibikase Therapeutics (IKT) Cash from Financing Activities (2020 - 2026) Analysis & Trends
On a trailing twelve-month basis, Inhibikase Therapeutics' Cash from Financing Activities was $111.31 million through Jun 30, 2026, up 11.4% year-over-year; for FY2025, it came in at $108.46 million, up 4.8% from FY2024.
- Cash from Financing Activities shows a five-year compound annual growth rate of 48.4% (FY2020 to FY2025).
- In earlier years, Cash from Financing Activities was $103.48 million in FY2024, $8.41 million in FY2023, -$204,769 in FY2022 and $41.09 million in FY2021 (+172.8%).
- Quarterly Cash from Financing Activities has moved between -$204,769 (Q1 2022) and $108.57 million (Q4 2025) over five years.
- Per Business Quant data, IKT's Cash from Financing Activities in the three quarters before Q2 2026 was $2.9 million (Q1 2026), $108.57 million (Q4 2025) and -$134,130 (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn | -8.78 Bn |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn | -5.05 Bn |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn | 1.76 Bn |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn | -2.02 Bn |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn | -47.00 Mn |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn | -1.48 Bn |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn | 2.34 Bn |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn | -3.66 Bn |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn | -426.70 Mn |
| 10 | Inhibikase Therapeutics | 359.62 Mn | -225.86 Mn | - | -14,489.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -14,489.00 |
| Mar 31, 2026 | 2.90 Mn |
| Dec 31, 2025 | 108.57 Mn |
| Sep 30, 2025 | -134,130.00 |
| Jun 30, 2025 | 31,771.00 |
| Dec 31, 2024 | 99.68 Mn |
| Sep 30, 2024 | 181,954.00 |
| Jun 30, 2024 | 3.24 Mn |
| Mar 31, 2024 | 366,999.00 |
| Dec 31, 2023 | -138,104.00 |
| Sep 30, 2023 | 70.00 |
| Jun 30, 2023 | -35,986.00 |
| Mar 31, 2023 | 8.58 Mn |
| Mar 31, 2022 | -204,769.00 |
| Sep 30, 2021 | 29,892.00 |
| Jun 30, 2021 | 41.47 Mn |
| Mar 31, 2021 | -409,662.00 |
| Dec 31, 2020 | 14.88 Mn |
| Sep 30, 2020 | -67,132.00 |
| Jun 30, 2020 | -2,450.00 |
API Access
Inhibikase Therapeutics Cash from Financing Activities API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=cash-from-financing-activities&ticker=IKT&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "cash-from-financing-activities", "ticker": "IKT", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=cash-from-financing-activities&ticker=IKT&period=max&api_key=YOUR_API_KEY");
const data = await res.json();